Companies: 10,795·Total market cap: $144.5T
Aldeyra Therapeutics, Inc.

Aldeyra Therapeutics, Inc.

ALDXNASDAQHealthcare● Active
$1.77
+$0.14(+8.28%)
Market Cap$106466685
P/E Ratio
52W High$6.175
52W Low$1.07
Overview

Aldeyra Therapeutics, Inc. (ALDX) Stock Overview

Key statistics and deep links to earnings, valuation, revenue, dividends, and more.

FMP · ALDX · as of Jun 8, 2026

Key Statistics

EPS (TTM)$-0.46aldx eps ttm · aldx earnings per shareEarnings history
PE Ratio (TTM)aldx pe ratio ttm · aldx price to earningsPE Ratio deep dive
Revenue (TTM)0.00aldx revenue ttm · aldx annual revenueFull revenue history
Dividend YieldNo Dividenddoes aldx pay dividends · aldx dividend yieldDividend history
Shares Outstanding60.1Maldx shares outstanding · aldx floatShares outstanding history
Next EarningsAug 6, 2026Est.aldx earnings date · aldx next earningsEarnings history

Financial Snapshot

Full Financials
FY 2025Revenue$0.00
202320242025
aldeyra therapeutics, inc. revenue · aldx revenue 2025
FY 2025Net Income-$33.8M▲ +39.40% YoY
202320242025
aldeyra therapeutics, inc. net income · aldx profit 2025
FY 2025EPS$-0.56▲ +40.43% YoY
202320242025
aldx eps · aldeyra therapeutics, inc. earnings per share 2025
TTM:Revenue: $0.00Net Income: -$27.4MEPS: $-0.46View income statement →

Analyst Ratings & Price Target

Full Forecast
SellBuy
Buy19 analystsis aldx a buy · aldx analyst rating
Strong Buy
0
Buy
18
Hold
1
Sell
0
Strong Sell
0
12-Month Price Target
$7.00Low
$1.76Current
$9.67Avg Target447.88% upside
$12.00High
aldx price target · aldx 12 month forecast

Total: 19 · Buy rate: 94.7%

The ALDX analyst consensus is Buy, based on ratings from 19 Wall Street analysts over the past 3 months. The average 12-month price target is $9.67, representing +447.88% upside from the current price of $1.76.

Stock Performance

Full History
1D+7.67%
1W+7.01%
1M+1.45%
3M-63.44%
YTD-66.12%
1Y-34.27%
5Y-86.47%

About Aldeyra Therapeutics, Inc.

CEOTodd C. Brady
IPO DateMay 2, 2014
Employees9
CountryUS

Aldeyra Therapeutics, Inc. a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a react…

what is aldeyra therapeutics, inc. · aldx stock overview · aldeyra therapeutics, inc. company profile · who is aldeyra therapeutics, inc. ceo · aldx NASDAQ · aldeyra therapeutics, inc. headquarters · aldeyra therapeutics, inc. business segments

About Stock Overview & Key Data

Aldeyra Therapeutics, Inc. (ALDX) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since May 2, 2014. As of the latest trading session, ALDX stock price is $1.76, with a market capitalization of $106.5M. The stock has returned -34.27% over the past 12 months and -66.12% year-to-date.

According to 19 Wall Street analysts, the consensus rating for Aldeyra Therapeutics, Inc. stock is Buy, with an average 12-month price target of $9.67. In fiscal year 2025, Aldeyra Therapeutics, Inc. reported revenue of — and net income of -$33.8M. For detailed data — including Aldeyra Therapeutics, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.

Frequently Asked Questions

As of the latest trading session, Aldeyra Therapeutics, Inc. (ALDX) stock price is $1.76. The stock is traded on NASDAQ under the ticker symbol ALDX. The 52-week range is $1.07 – $6.17.

ALDX stock priceALDX quote todaylive ticker
Data provided by Financial Modeling PrepLast updated: Jun 8, 2026Not investment advice